Takeda secures a fast review for new cancer drug; ReGenX eyes $121M in gene therapy IPO;

@FierceBiotech: Penn scientists identify viral products that defend against respiratory syncytial virus. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: Who you going to buy? Gilead banks $10B, stirring fresh buzz about a blockbuster buyout. Article | Follow @JohnCFierce

@DamianFierce: Flemming Ornskov, "avid postcard and letter writer" who keeps up on household chores. More | Follow @DamianFierce

> Takeda won the FDA's priority review designation for the multiple myeloma treatment ixazomib, guaranteeing a 6-month review time for the drug instead of the usual 10-month process. More

> Third Rock Ventures give Bloomberg a post-mortem on Ember Therapeutics, a once-promising biotech startup whose bet on a new treatment for obesity came up short. Story

> Gene therapy pioneer ReGenXBio updated the terms of its planned IPO, seeking up to $121.4 million to support its pipeline of rare disease treatments. News

Medical Device News

@FierceMedDev: Biogen CEO says the biotech aims to develop wearable and ingestible devices. More | Follow @FierceMedDev

@VarunSaxena2: Robotic surgery aspirant receives $4M+ in equity financing. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article | Follow @EmilyWFierce

> JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. More

> Delphinus raises $39M+ to back pivotal trial of more effective dense breast tissue ultrasound imaging. Article

Pharma News

@FiercePharma: ICYMI yesterday: Ireland plant with 100 workers on Sun's list for sale or closure. Item | Follow @FiercePharma

@EricPFierce: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Icahn casts his eye on Vivus with tender offer for convertible notes. More | Follow @CarlyHFierce

> Study: Patients sticking to their scripts saved Medicaid money. More

> Bernie Sanders unveils bill to battle rising drug prices. Article

Vaccines News

> UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target. Item

> With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs. Report

> VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine. Story

> Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs. Article

> Merck's Zostavax not cost-effective for those in their 50s: Study. More

CRO News

> Aragen licenses a protein technology to speed up biologics R&D. Item

> Rho snags a $120M federal contract with NIH. Story

> Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis. Article

> Icon teams up with IBM to accelerate clinical trial startup. News

> Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15. Article

Pharma Manufacturing News

> Bangladesh-based Square Pharmaceuticals has two new plants online. Item

> Canada allows Apotex Indian plants to regain access to its markets. More

> GSK recalls more than 425K tubes of antibiotic cream. Report

> Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article

> Glaxo starts $153M plant in India. Story

Pharma Asia News

> Japan's Takeda gets U.S. FDA priority review for ixazomib. Item

> FT counts 39 plants banned in India as regulatory woes mount for drugmakers. More

> China Daily carries lengthy industry-linked op-ed against overuse of stents. Report

> Apotex sees Health Canada lift ban on two India plants. Story

> Chugai and Roche get U.S. FDA priority review on alectinib. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

U.K.-based alpha-synuclein biotech Wren will partner with Japanese pharma Eisai to seek out new ways of targeting neuro disorders.

As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot’s efficacy figure.

Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors.